KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Depreciation & Amortization (2016 - 2026)

Supernus Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $91.6 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 13.86% to $91.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.6 million through Dec 2025, up 13.86% year-over-year, with the annual reading at $91.6 million for FY2025, 13.86% up from the prior year.
  • Accumulated Depreciation & Amortization was $91.6 million for Q4 2025 at Supernus Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $91.6 million in Q4 2025 and troughed at $500000.0 in Q2 2025.
  • The 5-year median for Accumulated Depreciation & Amortization is $1.8 million (2023), against an average of $18.2 million.
  • Year-over-year, Accumulated Depreciation & Amortization crashed 97.19% in 2023 and then surged 3297.17% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $32.6 million in 2021, then plummeted by 90.8% to $3.0 million in 2022, then surged by 2728.63% to $84.9 million in 2023, then decreased by 5.24% to $80.4 million in 2024, then increased by 13.86% to $91.6 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Accumulated Depreciation & Amortization are $91.6 million (Q4 2025), $1.6 million (Q3 2025), and $500000.0 (Q2 2025).